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Abstract
Background: Current studies about percutaneous endoscopic gastrostomy (PEG) tube placement report equivalent
patient outcomes with prophylactic PEG tubes (pPEGs) versus common nutritional support. Unreported was if
omitting a pPEG is associated with an increased risk of complications leading to a treatment-related unplanned
hospitalization (TRUH).
Methods: TRUHs were retrospectively analyzed in patients with advanced head and neck squamous cell carcinoma
(n=310) undergoing (chemo)radiotherapy with (pPEG) or without PEG (nPEG).
Results: In 88 patients (28%), TRUH was reported. One of the leading causes of TRUH in nPEG patients was
inadequate oral intake (n = 16, 13%), and in pPEG patients, complications after PEG tube insertion (n=12, 10%). Risk
factors for TRUH were poor performance status, tobacco use, and surgical procedures.
Conclusions: Omitting pPEG tube placement without increasing the risk of an unplanned hospitalization (UH) due to
dysphagia, dehydration or malnutrition, is an option in patients being carefully monitored . Patients aged >60 years
with hypopharyngeal carcinoma, tobacco consumption, and poor performance status appear at risk of PEG tube-
related complications leading to an unplanned hospitalization.
1 | Background
Curative intended radiotherapy (RT) with or without concomitant chemotherapy of patients with locoregionally
advanced (Union for International Cancer Control [UICC] 7th edition: stage III–IVB) head and neck squamous cell
carcinoma (HNSCC) may lead to malnutrition1,2, among other signi cant toxicities. An already existing dysphagia or
odynophagia caused by the tumor can be aggravated by therapy-related in ammation, mucositis, and edema along
the mucosal linings of the upper aero-digestive tract, as well as in the muscles of mastication and swallowing3-5. If
this leads to grade 3 dysphagia according to Common Terminology Criteria for Adverse Events (CTCAE version 5.0)6,
feeding tube or total parenteral nutrition and/or hospitalization is indicated. Several feeding tube strategies can be
used for this nutritional support (e.g. nasogastric tube, percutaneous endoscopic or percutaneous radiologic
gastrostomy). Retrospective analyses examining the indication for PEG tube placement showed differing results,
again making a conclusive statement challenging7. This is further complicated by the fact that a prophylactically
inserted PEG (pPEG) is sometimes found subsequently not to be needed8. A comprehensive review found weak
evidence concerning the pros and cons associated with pPEG placement and made a call for more prospective
studies9,10. One of the  rst prospective studies to include enough patients published its  rst results in 201210, with an
extended follow-up in 201711. The study compared the use of pPEGs with common nutritional support and enteral
tube feeding (when considered necessary) inserted after the start of treatment reactively (rPEG). It resulted in no
difference in swallowing function, tube dependence, and the prevalence of clinically relevant esophageal strictures.
There was no difference in weight, body mass index (BMI), or overall survival (OS) between the groups. There was
neither an advantage nor a disadvantage for a pPEG versus nPEG or a rPEG. However, in this study no complications
leading to a hospitalization were reported in the nPEG group. Our study aimed to analyze if omitting a PEG tube in
LAHNSCC patients was associated with an increased risk of complications leading to an unplanned hospitalization
(UH), compared to patients receiving a PEG tube prophylactically.
2 | Methods
2.1 | Patients
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In this retrospective single-center chart review, we identi ed a database of 310 consecutive UICC stage III–IVB HNSCC
patients (except for nasopharyngeal and sinonasal sites) treated between 2007 and 2012 with primary or adjuvant
chemo-RT with a curative intent. Ethics committee approval (Ref.-Nr. KEK-BE: 289/2014) was obtained for this study
and it has been conducted in full accordance with ethical principles, including the World Medical Association
Declaration of Helsinki (version 2002) and the additional requirements.
2.2 | Treatment and follow-up
Treatment strategies were based on institutional policies following the case-based multidisciplinary tumor board
decision, as previously published12,13. Patients who were  rst diagnosed before 2010 (UICC 6th edition) were re-
staged according to the 7th edition during data acquisition. During this period, there was no algorithm as to which
patient should be recommended for a pPEG. Prophylactic PEG placement was recommended to all patients based on
the subjective evaluation of their general condition, expected radiation volume and side effects by the attending
radiation oncologists. The cases in which a patient rejected a pPEG and the reasons of rejection were not
systematically assessed. The planning and delivery of RT as well as the de nitions of clinical target volume and
planned target volume followed international recommendations14-18. The RT was administered with 2 Gy daily
fractions using a volumetric modulated arc technique up to a total dose of 72 Gy for macroscopically detectable
tumor, 66 Gy for postoperative positive or narrow resection margin(s), and the lymph node region(s) with pathological
extracapsular extension. Elective nodal regions received 54 Gy. Sequential boosts were performed.
2.3 | Percutaneous endoscopic gastrostomy placement
Percutaneous endoscopic gastrostomy placements (pPEG and rPEG) were performed according to the pull method
described by Ponsky et al19. Antibiotic prophylaxis with Amoxicillin/Clavulanate 1.2 g intravenously and a Freka PEG
gastral 15 Ch/Fr EnFit (Fresenius Kabi, Switzerland) were routinely used.
2.4 | De nition of unplanned hospitalizations and follow-up
All complications leading to a hospitalization from the initial histopathological diagnosis to the last follow-up were
recorded. Emergency or unplanned admissions were de ned as unplanned hospitalizations (UHs). However, elective
hospitalizations, including those due to socially or logistically di cult circumstances (e.g. long journey, initially poor
general condition, etc.), were not analyzed. If an elective hospitalization was associated with a complication and
therefore an extension to the planned length of stay, the time from that complication to discharge was de ned as an
UH. UHs were classi ed as being related to comorbidities, index HNSCC and recurrences, or cancer treatment. When a
UH was related to cancer treatment, it was de ned as a treatment-related UH (TRUH). In order not to have more than
three endpoints and to enable a sound and simple statistical methodology, we analyzed only the  rst two UHs and
thus only the  rst two consecutive TRUHs in patients who had multiple UHs. In the case of externally UH, additional
information was obtained from the hospital where the emergency took place.
2.5 | Toxicities and the course of body weight
Toxicities and the course of body weight from the initial histopathological diagnosis to the last follow-up were
recorded and graded according to CTCAE (version 5.0)6. The patient’s weight was recorded before, during, and after
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therapy. Changes were graded by CTCAE: grade 1, 5% – <10% from baseline, intervention not indicated; grade 2, 10 –
≤20% from baseline, nutritional support indicated; grade 3 ≥20% from baseline, tube feeding, or total parenteral
nutrition indicated. Symptoms of pain, dermatitis, mucositis, dysphagia, xerostomia, and osteoradionecrosis were
assessed. Acute and late toxicities were de ned as post-treatment-related complications occurring during and/or
within 3 months or ≥3 months after commencing chemo-RT, respectively. Baseline pre-treatment tumor-related
morbidity using the same criteria were also assessed.
2.6 | Statistical analysis
Patients were grouped as pPEG and nPEG. Patients who received rPEG were included in the nPEG group according to
the intention-to-treat principle. The endpoints were de ned as:  rst TRUH (TRUH1), second consecutive TRUH
(TRUH2), and overall survival (OS). The start date of the  rst and second TRUH, and the date of death, were counted
as the corresponding time points, respectively. Cox’s proportional hazard model was used to evaluate time-to-event
endpoints, calculated from the date of histopathological diagnosis of the initial HNSCC. For multivariate analyses,
backwards stepwise elimination was performed by including variables yielding p values ≤0.05 in univariate analyses.
Actuarial time to event rates were depicted by Kaplan–Meier methodology. The chi-squared test was used to compare
categorical variables. All tests were two-tailed. No adjustment was done for multiple testing. Due to the lack of
concrete evidence or consensus regarding pre-treatment risk factors for feeding tube requirement to calculate and
assign propensity scores, no matched-pair analyses were performed. Statistical analyses were performed with JMP
(version 14.2.0; SAS Institute, Cary, NC, USA).
3 | Results
The median follow-up for the whole patient cohort was 32 months (range, 3-99 months). The median follow-up for the
nPEG and pPEG group was 35 (range, 3-94 months), and 32 months (range, 3-99 months), respectively. Table 1 shows
patient and disease characteristics. Compared with the nPEG group, the pPEG group had more patients aged 70 – 80
years, with a poor performance status (Eastern Cooperative Oncology Group performance status [ECOG PS] 2/3),
hypopharyngeal tumors, and more advanced T and N stages. The patients with pPEG received concomitant
chemotherapy more frequently and had less frequent grade 2 weight loss during therapy than nPEG patients. One
hundred forty-one of the 310 patients (46%) had at least one UH: 88 (28%) were TRUH1, 34 (11%) comorbidity-related,
and 19 (6%) relapse-related. Sixty-four patients (21%) had two consecutive UHs: 34 (11%) were TRUH2, 16 (5%)
comorbidity-related, and 14 (5%) relapse-related. Table 2 and Figure 1a show an overview of UHs; Table 3 and Figure
1b show an overview of TRUHs.
Beside chemo-RT-related side effects (dermatitis, mucositis, infection, pneumonia, and dyspnea), the leading causes
of TRUH in the nPEG group was dysphagia/dehydration/malnutrition. In the pPEG group, PEG complications were one
of the leading causes for TRUH, besides chemo-RT-related side effects (Table 3). The comparison of TRUH1
regardless of its cause was 80% vs. 70% (p=0.09) (Supplementary Figure 1). The comparison of TRUH1 related to
PEG complications or dysphagia/malnutrition/dehydration related events between nPEG and pPEG groups is shown
in Figure 2. There was no signi cant difference (p= 0.56). The same analysis was not repeated for TRUH2 due to the
small number of events (n=2). According to univariate analysis, risk factors for a TRUH were: poor ECOG PS (2/3),
tobacco use >40 pack-years (i.e. above the median), and surgical procedures ([bilateral] neck dissection,
tracheostomy, and pPEG). In multivariate analysis, tobacco use >40 pack-years, bilateral neck dissection, and poor
ECOG PS (2/3) remained as independent risk factors for TRUH. (Table 4). We investigated possible risk factors for a
PEG-associated event in a subgroup analysis, which revealed that tumor localization to hypopharynx (P=.0183),
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active tobacco consumption (P=.0009), tobacco use >40 pack-years (P=.0001), poor ECOG PS (2/3) (P=.0418), and
age >60 years (P=.0352) were risk factors in the univariate analysis (data not shown). Overall survival at 3 years for
the entire, nPEG, and pPEG group was 70%, 67%, and 73%, respectively. Overall survival was associated with age,
ECOG PS 2-3, tumor localization to the oropharynx and hypopharynx, neck dissection, rPEG, and baseline BMI (Table
4).
4 | Discussion
In a relatively large cohort of 310 patients with locoregionally advanced HNSCC compared with previously published
studies7,9,20-23, we retrospectively analyzed whether omitting a PEG compared to prophylactic PEG insertion is
associated with an increased risk of complications leading to a TRUH. Although the institutional policy was to offer
pPEG to all patients with locoregionally advanced HNSCC, physicians were less keen on insisting that patients with a
possibly lower risk pro le should receive a pPEG. Moreover, some patients refused the pPEG regardless of their risk
pro le. Therefore, pPEG placement tended to be used more frequently in patients with a higher risk pro le and worse
prognosis (comprising general condition, tumor size, age, hypopharyngeal tumor localization; Table 1). In the nPEG
group, apart from (chemo)-RT-related side effects, dysphagia/dehydration/malnutrition (n=8; 20%) was the most
frequent cause of TRUH, whereas in the pPEG group, apart from (chemo)-RT-related side effects, PEG-related
complications frequently led to TRUH (n=11; 14%). There was no difference in TRUH caused by PEG complications or
dysphagia/malnutrition/dehydration after pPEG vs. nPEG (p = 0.56). PEG tube placement is associated with the risk
of complications; however, there is a great deal of variability in the reported incidence of such complications11,20,24-29.
The difference in the incidences of complications is partly due to the various de nitions and populations analyzed.
For example, complications are more likely to occur in older patients with comorbidities, especially those with an
infection or history of aspiration30. Compared with the publication of Silander et al.10, our rate of PEG-related
complications is relatively high (14% versus 1%); however, it is relatively low compared with a prospective study
reporting complication rates at 2 weeks and 2 months (39% and 27%, respectively)24. We hypothesize that our pPEG
cohort is a different, more fragile patient population that tends to have more complications compared with that
studied by Silander et al.10 and our nPEG population. Furthermore, we suspect that patients – like those studied by
our Swedish colleagues10 – who are willing to be included and randomized in a study, are more compliant than the
patients with HNSCC seen in our everyday practice, over two-thirds of whom have a positive history of alcohol abuse
and more than 87% a positive history of tobacco use31. Patients with severe clinical and psychosocial impairment
and fewer economic resources are more likely to experience treatment compliance problems31. There is an increasing
incidence of oropharyngeal cancer, especially in younger patients, and a decrease in the previously known risk factors
for HNSCC of smoking and alcohol use32,33. Previously, typical patients with HNSCC tended to be heavy drinkers or
smokers; however, human papillomavirus (HPV)-associated HNSCC in younger,  tter, and possibly more compliant
patients increasingly represent the majority of at least oropharyngeal disease34.  This interesting aspect should be
kept in mind before considering that in our entire cohort, up to one- fth of patients had a TRUH besides the (chemo)-
RT-induced TRUH – due to dysphagia/dehydration/malnutrition (20%) in the nPEG group or postoperatively after PEG
insertion (12%) in the pPEG group. The physician and patient have to face the additional risks associated with an
invasive procedure, such as PEG tube placement, or those arising from not performing a supportive surgical procedure
to allow su cient oral intake, such as dysphagia/dehydration/malnutrition.
Further differences between our cohort and the Swedish study10,11 can be seen with regard to weight loss, BMI, and
OS between the pPEG and nPEG groups. The increased weight loss and BMI differences during RT in the nPEG versus
pPEG groups could be explained not only by the greater compliance of patients but also by the prospective setting –
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and therefore thorough monitoring by nutrition counselors in the nPEG cohort – of the Silander et al. trial10. Nutrition
counselors were not systematically involved in the treatment of our patients, and some patients categorically refused
nutrition counseling. The higher risk pro le in the pPEG group more easily explains the OS difference versus the nPEG
group (tumor size, age, tumor localization; Table 1), as OS is known to be worse in patients with larger primary tumors
and hypopharyngeal tumor35-38. Other limitations of our study, apart from the different risk pro les of the nPEG and
pPEG groups, include its retrospective nature, the lack of strati cation according to HPV status, and the presence of
some patients treated with surgery before RT.
With future changes in the HNSCC population, therapy regimens, and side-effect pro le according to the HPV status,
further analyses of the indication for a PEG is necessary39.
5 | Conclusions
Our retrospective analysis shows that omitting a prophylactic PEG does not lead to more unplanned hospitalizations
compared to patients receiving a PEG tube before start of chemoradiation. Patients with a hypopharyngeal
carcinoma, active tobacco consumption, more than 40 pack-years of smoking history, and poor ECOG PS seem to be
at risk of PEG tube-related UH. Prospective trials about pPEG, especially for oropharyngeal carcinoma and its future
results concerning de-escalation, are warranted.
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Tables
TABLE 1           Patient and disease characteristics 
Page 10/19
Characteristic
All patients
(n=310)
pPEG 
 (n=175)
nPEG or rPEG
(n=135) P value
Age at first diagnosis, years        
     Median (range) 61 (20–94) 62 (20–83) 61 (40–94) ns
     ≤60, n (%) 139 (44) 75 (43) 64 (47) ns
     >60–≤70, n (%) 111 (36) 36 (37) 47 (35) ns
     >70–≤80, n (%) 45 (15) 32 (18) 13 (10) .035
     >80, n (%) 15 (5) 4 (2) 11 (8) .029
Sex, n (%)        
     Female 75 (24) 129 (74) 106 (79) ns
     Male 235 (76) 46 (26) 29 (21) ns
ECOG performance status, n (%)        
     0 112 (36) 56 (32) 56 (43) ns
     1 153 (50) 87 (50) 66 (50) ns
     2/3 40 (14) 30 (18) 9 (7) .006
     Missing, n 5 1 4 na
Median (range) baseline BMI, kg/m2 24.9 (16.8–
38.7)
24.9 (16.8–
38.6)
24.9 (17.6–36.8) ns
Body weight loss during RT, CTCAE
grade, n (%)
       
     0 135 (47) 92 (55) 43 (36) .002
     1 87(30) 48 (29) 39 (33) ns
     2 62 (22) 26 (15) 36 (30) .004
     3 2 (1) 1 (1) 1 (1) ns
     Missing, n 24 8 16 na
Smoking habits        
     Never smoker 34 (13) 21 (13) 13 (12) ns
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     Ex-smoker 75 (29) 47 (30) 28 (26) ns
     Current smoker 153 (58) 87 (56) 66 (62) ns
     Missing, n 48 20 28 na
Tobacco use, pack-years        
     Median (range) 40 (0–150) 40 (0–150) 40 (0–120) ns
     >40 (i.e. above median), n (%) 100 (44) 65 (46) 35 (41) ns
     Missing, n 83 34 49 ns
Alcohol abuse, n (%)        
     No 85 (33) 54 (35) 31 (31) ns
     In the past 23 (9) 15 (10) 8 (8) ns
     Yes 147 (58) 85 (55) 62 (61) ns
     Missing, n 55 21 34 na
Tumor localization, n (%)        
     Oral cavity 63 (20) 36 (21) 27 (20) ns
     Oropharynx 149 (48) 77 (44) 72 (53) ns
     Hypopharynx 44 (14) 33 (19) 11 (8) .008
     Larynx 39 (13) 16 (9) 23 (17) ns
     Multi-compartemental 15 (5) 13 (7) 2 (2) .016
Tumor category, n (%)        
     T1 25 (8) 9 (5) 16 (12) .036
     T2 95 (31) 42 (24) 53 (39) .004
     T3 102 (33) 59 (34) 43 (32) ns
     T4 88 (28) 65 (37) 23 (17) <.001
Nodal category, n (%)        
     N0 36 (12) 17 (10) 19 (14) ns
     N1 55 (18) 21 (12) 34 (25) .004
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     N2 206 (66) 128 (73) 77 (57) .003
     N3 11 (4) 9 (5) 5 (4) ns
UICC stage (7th Edition), n (%)        
     III 65 (21) 22 (13) 43 (32) <.001
     IVA 228 (74) 142 (81) 86 (64) <.001
     IVB 17 (5) 11 (6) 6 (4) ns
Surgical interventions, n (%)        
     Primary oncologic resection  78 (25) 42 (27) 36 (27) ns
     Neck dissection 214 (69) 121 (69) 93 (69) ns
PEG tube placement, n (%)        
     Prophylactic 175 (56) 175 (100) 0 (0) na
     Reactive 34 (11) 0 (0) 34 (25) na
     None 101 (33) 0 (0) 101 (75) na
Median (range) duration of PEG
dependency, days 
266 (4–2969) 274 (40–
2969)
231 (4–2554) <.001
Chemotherapy, n (%)        
     Concomitant 266 (86) 161 (92) 105 (78) <.001
     Neoadjuvant 33 (11) 21 (12) 12 (9) ns
Abbreviations: BMI, body mass index; CTCAE, Common Terminology Criteria for Adverse Events; na,
not applicable; ns, not significant; nPEG, no PEG; PEG, percutaneous endoscopic gastrostomy; pPEG,
prophylactic PEG; rPEG, reactive PEG; RT, radiotherapy; UICC, Union for International Cancer
Control.
 
 
 
TABLE 2            Overview of unplanned hospitalizations (n=310)
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UH 
No. of patients (%) All UHs, 
 No. of events (%)UH1 UH2
Any UH 141 (45) 64 (21) 205 events in 169 patients
Reason for UH      
            Comorbidity-related 34 (11) 16 (5) 50 (24)
                        Alcoholism 4 (12) 0 (0) 4 (8)
                        Cardiopulmonary 9 (27) 3 (19) 12 (24)
                        Gastrointestinal 4 (12) 0 (0) 4 (8)
                        Infection 12 (35) 5 (31) 17 (34)
                        Other 5 (14) 8 (50) 13 (26)
            Related to tumor or relapse 19 (6) 14 (4) 33 (16)
            Treatment-related (TRUH) 88 (28) 34 (11) 122 (60)
                        Due to PEG 11 (13) 1 (2) 12 (10)
                        Due to surgery 3 (3) 1 (3) 4 (3)
                        Due to neoadjuvant CX 4 (4) 2 (6) 6 (5)
                        Due to radio-CX 70 (80) 29 (85) 99 (81)
Abbreviations: CX, chemotherapy; TRUH, treatment-related unplanned hospitalization; UH, unplanned
hospitalization; UH1, first UH event; UH, second UH event.
 
 
TABLE 3           Details of TRUHs (n=310)
Page 14/19
Reason for TRUH
All patients
 (n=310)
pPEG
 (n=175)
nPEG or rPEG
 (n=135)
No. (%) No. (%) No. (%)
TRUH1 (n=88)            
Dermatitis/mucositis/oral infection 18 (20) 13 (23) 5 (16)
Dysphagia/dehydration/malnutrition 15 (17) 7 (12) 8 (26)
General condition 8 (9) 5 (9) 3 (10)
Osteonecrosis/dental caries 8 (9) 5 (9) 3 (10)
Other 11 (11) 7 (13) 4 (13)
Percutaneous endoscopic gastrostomy 11 (14) 9 (16) 2 (6)
Pneumonia/dyspnea 17 (19) 11 (19) 6 (19)
Total 88 (28) 57 (33) 31 (23)
TRUH2 (n=34)            
Dermatitis/mucositis/oral infection 3 (9) 3 (13) 0 (0)
Dysphagia/dehydration/malnutrition 1 (3) 1 (4) 0 (0)
General condition 4 (12) 2 (8) 2 (20)
Osteonecrosis/dental caries 6 (18) 3 (13) 3 (30)
Percutaneous endoscopic gastrostomy 3 (9) 0 (0) 1 (10)
Pneumonia/dyspnea 14 (41) 11 (46) 3 (30)
Other 3 (9) 4 (17) 1 (10)
Total 34 (11) 24 (14) 10 (7)
All TRUHs (n=122)            
Dermatitis/mucositis/oral infection 21 (17) 16 (20) 5 (12)
Dysphagia/dehydration/malnutrition 16 (13) 8 (10) 8 (20)
General condition 12 (10) 7 (9) 5 (12)
Osteonecrosis/dental caries 14 (11) 8 (10) 6 (15)
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Percutaneous endoscopic gastrostomy 12 (12) 11 (14) 1 (10)
Pneumonia/dyspnea 31 (25) 22 (27) 9 (22)
Other 13 (11) 9 (11) 4 (10)
Total number 122 (–)  81 (–) 41 (–)
Abbreviations: na, not applicable; ns, not significant; TRUH, treatment-related unplanned
hospitalization; TRUH1, first TRUH event; TRUH2, second TRUH event; nPEG, no percutaneous
endoscopic gastrostomy; pPEG, prophylactic percutaneous endoscopic gastrostomy; rPEG, reactive
percutaneous endoscopic gastrostomy.
 
 
TABLE 4           Univariate and multivariate analysis (Cox proportional-hazard)
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Variable
TRUH1 TRUH2 OS
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
Univariate
Age, years            
≤60 0.76 (0.48–
1.18)
.21 0.74 (0.35–
1.56)
.42 0.63 (0.42–
0.96)
.0288
>60–≤70 1.00 (0.64–
1.58)
.99 1.07 (0.51–
2.67)
.86 0.92 (0.60–
1.40)
.6884
>70–≤80 1.43 (0.82–
2.50)
.20 1.59 (0.65–
3.91)
.30 1.40 (0.84–
2.34)
.1937
>80 1.52 (0.61–
3.75)
.35 0.80 (0.11–
5.85)
.82 4.25 (2.26–
7.99)
.0001
ECOG PS at first consultation, (vs other PS)        
0 0.95 (0.60–
1.51)
.83 0.89 (0.41–
1.91)
.76 0.64 (0.41–
1.00)
.0475
1 (vs others) 0.73 (0.47–
1.14)
.16 0.59 (0.28–
1.26)
.17 1.05 (0.71–
1.58)
.7939
2/3 (vs others) 1.99 (1.15–
3.45)
.01 2.77 (1.23–
6.27)
.01 2.01 (1.21–
3.37)
.0061
Alcohol abuse            
Active 1.16 (0.71–
1.88)
.55 0.81 (0.36–
1.83)
.60 1.23 (0.78–
1.94)
.3783
Active or in past 1.59 (0.92–
2.75)
.09 1.17 (0.48–
2.85)
.72 1.33 (0.82–
2.16)
.2475
>2 units a day (=median) 1.44 (0.81–
2.57)
.21 0.84 (0.30–
2.35)
.73 1.06 (0.63–
1.79)
.8203
Smoking habits            
Current smoker 1.13 (0.70–
1.82)
.61 0.94 (0.41–
2.13)
.87 1.06 (0.68–
1.66)
.7832
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Current or ex-smoker 1.68 (0.74–
3.92)
.20 3.39 (0.46–
25.1)
.20 1.14 (0.59–
2.21)
.7022
>40 pack-years
(=median)
1.94 (1.17–
3.20)
.01 1.98 (0.81–
4.85)
.12 1.01 (0.63–
1.63)
.9615
Tumor localization, yes (vs no)          
Oral cavity 1.06 (0.62–
1.81)
.83 0.81 (0.31–
2.12)
.67 0.80 (0.48–
1.36)
.409
Oropharynx 0.75 (0.48–
1.17)
.19 0.75 (0.36–
1.56)
.43 0.63 (0.42–
0.95)
.026
Hypopharynx 1.43 (0.81–
2.50)
.20 2.00 (0.86–
4.69)
.10 1.81 (1.11–
2.93)
.0149
Larynx 1.21 (0.66–
2.23)
.53 0.79 (0.24–
2.60)
.69 1.39 (0.81–
2.38)
.2251
Mixed 0.80 (0.25–
2.52)
.69 1.60 (0.38–
6.73)
.56 1.81 (0.74–
4.48)
.1878
Surgery, yes (vs no)            
Primary oncologic
surgery 
0.72 (0.42–
1.24)
.22 0.47 (0.16–
1.34)
.15 0.79 (0.49–
1.29)
.3395
Neck dissection 0.69 (0.44–
1.07)
.09 0.47 (0.23–
0.96)
.03 0.66 (0.44–
0.99)
.0438
Bilateral ND 1.69 (1.08–
2.64)
.00 1.75 (0.84–
3.67)
.13 0.92 (0.58–
1.45)
.7161
Tracheostomy 1.78 (1.15–
2.77)
.01 2.58 (1.24–
5.35)
.01 1.49 (0.98–
2.25)
.0594
pPEG 1.46 (0.93–
2.30)
.09 2.56 (1.09–
5.99)
.02 1.24 (0.82–
1.86)
.3003
rPEG 2.54 (1.48–
4.33)
.00 1.75 (0.67–
4.58)
.25 2.07 (1.25–
3.43)
.0038
Chemotherapy, yes (vs no)          
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Neoadjuvant 1.53 (0.83–
2.83)
.57 2.82 (1.20–
6.60)
.01 1.26 (0.69–
2.31)
.4535
Concomitant 1.22 (0.61–
2.43)
.16 2.08 (0.50–
8.76)
.30 0.59 (0.35–
1.02)
.054
Baseline BMI, kg/m2            
≤18.5 1.11 (0.27–
4.54)
.89 1.46 (0.20–
10.8)
.71 3.42 (1.23–
9.50)
.0115
>18.5–<25 0.70 (0.41–
1.22)
.20 0.73 (0.30–
1.73)
.46 0.94 (0.56–
1.58)
.8135
≥25 1.39 (0.81–
2.38)
.22 1.29 (0.55–
3.02)
.55 0.88 (0.53–
1.47)
.6231
Multivariate
Model 1 for TRUH1          
ECOG 2/3 1.73 (0.93–
3.23)
.10 - - - -
>40 pack-years 1.94 (1.17–
3.20)
.01 - - - -
Bilateral ND 1.69 (1.02–
2.78)
.04 - - - -
Model 2 for TRUH2          
ECOG 2/3 - - 2.77 (1.23-
6.27)
.03 - -
pPEG - - 2.06 (0.87-
4.91)
.09 - -
Neoadjuvant CX - - 3.27 (1.38-
7.74)
.02 - -
Model 3 for OS          
Age >80 years - - - - 4.25 (2.26-
7.99)
.00
Page 19/19
ECOG 2/3 - - - - 1.64 (0.94-
2.85)
.10
rPEG - - - - 1.95 (1.18-
3.25)
.02
             
Note: P values in bold are significant at P<0.05.
Abbreviations: BMI, body mass index; CI, confidence interval; ECOG PS, Eastern Cooperative
Oncology Group performance status; HR, hazard ratio; OS, overall survival; TRUH, treatment-related
unplanned hospitalization; TRUH1, first TRUH event; TRUH2, second TRUH event; pPEG, prophylactic
percutaneous endoscopic gastrostomy; rPEG, Reactive percutaneous endoscopic gastrostomy; ND,
neck dissection; CX, chemotherapy. 
 
